Trials that use: Mixed-effects model
New to this method? Read the tutorial →
35 results
- AWARD-6Independent statistical analysis of the randomized phase 3 AWARD-6 trial comparing dulaglutide with liraglutide in type 2 diabetes, including the HbA1c non-inferiority analysis, secondary endpoints, statistical methods, safety, and interpretation.
- CAPRISA 008Independent statistical analysis of CAPRISA 008, a randomized phase 2/3 trial evaluating 1% tenofovir gel provision through family planning services for HIV prevention, including adherence, HIV incidence, pregnancy, HPV, and safety analyses.
- EMBRACAIndependent statistical analysis of the EMBRACA phase 3 trial of talazoparib versus physician's choice treatment in advanced and/or metastatic breast cancer patients with BRCA mutation, including progression-free survival, response, overall survival, quality…
- EMPEROR-ReducedIndependent statistical analysis of EMPEROR-Reduced, a randomized phase 3 trial of empagliflozin versus placebo in chronic heart failure with reduced ejection fraction. Includes the registered time-to-event endpoint, Cox and mixed-effects analyses, reported…
- EMPULSEIndependent statistical analysis of the EMPULSE phase 3 trial of empagliflozin in patients hospitalized for acute heart failure, including the primary win-ratio endpoint, secondary analyses, statistical methodology, safety, and interpretation.
- EVOLVE-1Independent statistical analysis of the phase 3 EVOLVE-1 trial of galcanezumab for the prevention of episodic migraine, including randomized design, longitudinal mixed-effects analysis, odds ratios, Fisher exact testing, efficacy results, safety, and…
- EVOLVE-2Independent statistical analysis of the phase 3 EVOLVE-2 trial of galcanezumab for the prevention of episodic migraine, including trial design, registered endpoints, mixed-effects analyses, confidence intervals, secondary outcomes, safety information, and statistical…
- EXPEDITION 3Independent statistical analysis of EXPEDITION 3 (NCT01900665), a randomized phase 3 trial comparing solanezumab with placebo in participants with mild Alzheimer's disease, including the registered ADAS-Cog14 endpoint, mixed-effects analysis, confidence interval, p-value,…
- FINEARTS-HFIndependent statistical analysis of FINEARTS-HF, the randomized phase 3 trial evaluating finerenone versus placebo in participants with heart failure and left ventricular ejection fraction greater than or equal to 40%.
- GALACTIC-HFIndependent statistical analysis of GALACTIC-HF, the randomized phase 3 trial of omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, including time-to-event methods, KCCQ analysis, confidence intervals, multiplicity, and safety.
- INBUILDIndependent statistical analysis of the INBUILD phase 3 trial of nintedanib in patients with progressive fibrosing interstitial lung disease, including FVC decline, longitudinal modeling, time-to-event endpoints, logistic regression, safety, and interpretation.
- iPrExIndependent statistical analysis of the randomized phase 3 iPrEx trial of daily TDF/FTC versus placebo for HIV prevention in men, including primary efficacy and safety endpoints, secondary analyses, statistical methods, and interpretation.
- ISABELA 1Independent statistical analysis of ISABELA 1 (NCT03711162), a randomized phase 3 study of GLPG1690 in idiopathic pulmonary fibrosis, including FVC decline, disease progression, hospitalization, mixed-effects models, logistic regression, Cox models, and safety.
- ISABELA 2Complete statistical analysis of the ISABELA 2 phase 3 trial of GLPG1690 in idiopathic pulmonary fibrosis, including trial design, FVC decline, disease progression, hospitalization, survival endpoints, safety, statistical methodology, and interpretation.
- LUX-Lung 7Independent statistical analysis of LUX-Lung 7, the randomized phase 2 trial comparing afatinib with gefitinib in first-line EGFR mutation-positive lung adenocarcinoma, including survival, response, quality-of-life, and safety analyses.
- MA.17Independent statistical analysis of MA.17, a randomized phase 3 trial evaluating letrozole versus placebo in women with breast cancer who had received 5 years of aromatase inhibitor therapy, including disease-free survival, overall…
- MONARCH 3Independent statistical analysis of the phase 3 MONARCH 3 trial of abemaciclib plus a nonsteroidal aromatase inhibitor in postmenopausal women with breast cancer, including progression-free survival, response, health-status outcomes, methodology, safety, and…
- OlympiADIndependent statistical analysis of the OlympiAD phase 3 trial of olaparib monotherapy versus physician's choice chemotherapy in metastatic breast cancer patients with germline BRCA1/2 mutations.
- PALOMA-2Independent statistical analysis of PALOMA-2 (NCT01740427), a randomized phase 3 trial of palbociclib plus letrozole versus placebo plus letrozole in postmenopausal women with ER+/HER2- advanced breast cancer.
- PALOMA-4Independent statistical analysis of PALOMA-4, a randomized phase 3 trial comparing palbociclib plus letrozole with placebo plus letrozole in Asian postmenopausal women with ER+/HER2- advanced breast cancer.
- PARAGON-HFIndependent statistical analysis of PARAGON-HF, evaluating LCZ696 versus valsartan in heart failure with preserved ejection fraction, including primary and secondary endpoint analyses, statistical methods, interpretation, and limitations.
- Partners PrEPAn independent statistical analysis of the Partners PrEP phase 3 trial, examining TDF and FTC/TDF for prevention of HIV-1 acquisition in HIV-1 discordant couples, including Cox regression, hazard ratios, safety, longitudinal analyses,…
- PROFILE 1014Independent statistical analysis of PROFILE 1014, evaluating crizotinib versus pemetrexed plus cisplatin or carboplatin in ALK-positive non-squamous lung cancer, with detailed interpretation of progression-free survival, overall survival, response, patient-reported outcomes, and statistical…
- RATIONALE-301Independent statistical analysis of RATIONALE-301, a randomized phase 3 trial of tislelizumab versus sorafenib in participants with unresectable hepatocellular carcinoma, including overall survival, response, progression, quality of life, and the trial's non-inferiority…
- RATIONALE-303Independent statistical analysis of RATIONALE-303, a randomized phase 3 trial comparing tislelizumab with docetaxel in second- or third-line non-small cell lung cancer, including overall survival, response, progression-free survival, quality of life, and…
- RED-HFIndependent statistical analysis of the RED-HF phase 3 trial of darbepoetin alfa in heart failure, including trial design, time-to-event endpoints, hazard ratios, KCCQ analyses, safety, methodology, and statistical interpretation.
- SOLO1Complete statistical analysis of SOLO1, a randomized phase 3 trial of olaparib maintenance monotherapy versus placebo in BRCA-mutated advanced ovarian cancer following first-line platinum-based chemotherapy.
- STRIVEComplete statistical analysis of the STRIVE phase 3 trial of erenumab for migraine prevention, including randomized trial design, primary and secondary endpoint analyses, mixed-effects models, Cochran-Mantel-Haenszel testing, multiplicity, and safety.
- SURMOUNT-3Independent statistical analysis of the phase 3 SURMOUNT-3 trial of tirzepatide in participants with obesity or overweight after a lifestyle weight loss program, including trial design, primary endpoints, reported estimates, statistical methods,…
- SURPASS-3Complete statistical analysis of SURPASS-3, a randomized phase 3 trial comparing tirzepatide with insulin degludec in participants with type 2 diabetes, including HbA1c, body weight, fasting serum glucose, treatment satisfaction, statistical methodology,…
- SURPASS-4Independent statistical analysis of SURPASS-4, a randomized phase 3 trial of once-weekly tirzepatide versus once-daily insulin glargine in participants with type 2 diabetes and increased cardiovascular risk.
- SURPASS-5Complete statistical analysis of SURPASS-5, a randomized phase 3 trial of tirzepatide versus placebo in participants with type 2 diabetes inadequately controlled on insulin glargine with or without metformin.
- SUSTAIN-3Independent statistical analysis of SUSTAIN-3, the randomized phase 3 trial comparing once-weekly semaglutide 1.0 mg with exenatide ER 2.0 mg in subjects with type 2 diabetes receiving 1–2 oral antidiabetic drugs.
- SUSTAIN-7Independent statistical analysis of the SUSTAIN-7 phase 3 trial comparing semaglutide with dulaglutide as add-on to metformin in subjects with type 2 diabetes, including mixed-effects modeling, non-inferiority and superiority testing, confidence intervals,…
- TRAILBLAZER-ALZ 2A detailed statistical analysis of TRAILBLAZER-ALZ 2, a randomized phase 3 study of donanemab versus placebo in participants with early Alzheimer's disease, including endpoint results, mixed-effects models, ANCOVA, confidence intervals, and interpretation.